Payment overview · 2025
General Payments
$2,855.12
105 reported records · 27 companies
Healthcare provider profile · identity verified
Rafael Rodriguez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON HEIGHTS, NY · NPI 1144298175
Verified facts
What the public records show
CMS Open Payments records show Rafael Rodriguez, MD received $2,855.12 in general payments during 2025 across 105 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $735.09 | 25.8% | 19 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $337.23 | 11.8% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $258.40 | 9.1% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.46 | 6.9% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $178.08 | 6.2% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$176.58 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.86 | 4.8% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $118.19 | 4.1% | 5 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $109.68 | 3.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $90.26 | 3.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.52 | 2.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.94 | 2.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.06 | 1.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.17 | 1.4% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $38.84 | 1.4% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $29.51 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.54 | 1.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.09 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.68 | 0.8% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $22.31 | 0.8% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.09 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.21 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.64 | 0.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.67 | 0.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.30 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.72 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,855.12 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $366.12 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $337.23 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $324.25 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $258.40 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $204.29 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $196.46 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $177.48 | 8 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $176.58 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $109.68 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $90.26 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $79.86 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.52 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $61.99 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.72 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $38.84 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 20 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 146 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 88 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 152 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 141 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 452 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
110 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
152 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
141 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
431 | 98 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
146 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
113 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
152 | 32 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
88 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
452 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
146 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2071 | 634 |
| Amlodipine Besylate | Amlodipine Besylate | 1073 | 316 |
| Metformin Hcl | Metformin Hcl | 1061 | 308 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 896 | 263 |
| Losartan Potassium | Losartan Potassium | 756 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 196 |
| Omeprazole | Omeprazole | 624 | 220 |
| Simvastatin | Simvastatin | 537 | 153 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 519 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 155 |
| Ozempic | Semaglutide | 452 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 446 | 144 |
| Carvedilol | Carvedilol | 441 | 130 |
| Synjardy | Empagliflozin/Metformin Hcl | 431 | 98 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 426 | 122 |
| Meloxicam | Meloxicam | 386 | 152 |
| Zolpidem Tartrate | Zolpidem Tartrate | 366 | 69 |
| Quetiapine Fumarate | Quetiapine Fumarate | 362 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 359 | 126 |
| Gabapentin | Gabapentin | 334 | 101 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 319 | 117 |
| Lisinopril | Lisinopril | 312 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 254 | 116 |
| Isoniazid | Isoniazid | 251 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 77 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 232 | 68 |
| Valsartan | Valsartan | 226 | 69 |
| Ezetimibe | Ezetimibe | 224 | 68 |
| Glimepiride | Glimepiride | 212 | 66 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 211 | 64 |
| Famotidine | Famotidine | 208 | 80 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 206 | 61 |
| Single Use Swab | Alcohol Antiseptic Pads | 205 | 91 |
| Meclizine Hcl | Meclizine Hcl | 202 | 75 |
| Azithromycin | Azithromycin | 197 | 157 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 197 | 53 |
| Glipizide | Glipizide | 192 | 55 |
| Montelukast Sodium | Montelukast Sodium | 185 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 48 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 164 | 43 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 163 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 47 |
| Farxiga | Dapagliflozin Propanediol | 152 | 53 |
| Trulicity | Dulaglutide | 152 | 32 |
| Ibuprofen | Ibuprofen | 150 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 41 |
| Eliquis | Apixaban | 146 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 144 | 59 |
| Kerendia | Finerenone | 141 | 41 |
| Jardiance | Empagliflozin | 137 | 45 |
| Mometasone Furoate | Mometasone Furoate | 137 | 47 |
| Finasteride | Finasteride | 135 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 43 |
| Methylprednisolone | Methylprednisolone | 134 | 117 |
| Donepezil Hcl | Donepezil Hcl | 131 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 130 | 37 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 125 | 30 |
| Alprazolam | Alprazolam | 123 | 33 |
| Furosemide | Furosemide | 123 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 55 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 113 | 89 |
| Linzess | Linaclotide | 110 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 37 |
| Ketoconazole | Ketoconazole | 106 | 32 |
| Memantine Hcl | Memantine Hcl | 105 | 43 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 104 | 92 |
| Clonazepam | Clonazepam | 101 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 30 |
| Mounjaro | Tirzepatide | 100 | 24 |
| Januvia | Sitagliptin Phosphate | 98 | 22 |
| Jentadueto | Linagliptin/Metformin Hcl | 96 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 29 |
| Ammonium Lactate | Ammonium Lactate | 94 | 43 |
| Vascepa | Icosapent Ethyl | 93 | 27 |
| Xarelto | Rivaroxaban | 91 | 25 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 91 | 21 |
| Nifedipine Er | Nifedipine | 90 | 26 |
| Entresto | Sacubitril/Valsartan | 88 | 26 |
| Naproxen | Naproxen | 87 | 37 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 83 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 21 |
| Synthroid | Levothyroxine Sodium | 79 | 27 |
| Novolog Flexpen | Insulin Aspart | 75 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 21 |
| Atenolol | Atenolol | 73 | 18 |
| Prednisone | Prednisone | 73 | 38 |
| Gemfibrozil | Gemfibrozil | 70 | 23 |
| Chlorthalidone | Chlorthalidone | 68 | 21 |
| Tradjenta | Linagliptin | 68 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 67 | 16 |
| Celecoxib | Celecoxib | 66 | 22 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 66 | 15 |
| Labetalol Hcl | Labetalol Hcl | 65 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 63 | 17 |
| Nateglinide | Nateglinide | 62 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 59 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 17 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 58 | 23 |
| Ramipril | Ramipril | 57 | 19 |
| Repaglinide | Repaglinide | 57 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 15 |
| Pregabalin | Pregabalin | 55 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 54 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 11 |
| Mirtazapine | Mirtazapine | 51 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 11 |
| Irbesartan | Irbesartan | 47 | 15 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Megestrol Acetate | Megestrol Acetate | 46 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 15 |
| Ciclopirox | Ciclopirox Olamine | 41 | 23 |
| Valacyclovir | Valacyclovir Hcl | 41 | 21 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 40 | 39 |
| Trazodone Hcl | Trazodone Hcl | 40 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 15 |
| Enalapril Maleate | Enalapril Maleate | 39 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Risperidone | Risperidone | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 37 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 21 |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 15 |
| Procto-Med Hc | Hydrocortisone | 32 | 11 |
| Sertraline Hcl | Sertraline Hcl | 32 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 31 | 31 |
| Cilostazol | Cilostazol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 18 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 26 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Proctozone-Hc | Hydrocortisone | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 12 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | 11 |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Terconazole | Terconazole | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Dexilant | Dexlansoprazole | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,855.12 · 105 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, GARDASIL 9, HAWKONE, IBSRELA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, Paradise Ultrasound Renal Denervation System, REPATHA, Rybelsus, SHINGRIX, SKYCLARYS, Symbravo, UNITHROID, VRAYLAR, Veltassa, ZAVZPRET, ZENPEP, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error